Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 microg plus formoterol 6 microg/actuation), 2 puffs b.i.d., versus beclomethasone diproprionate HFA (250 microg/actuation), 4 puffs b.i.d., versus Seretide 500/50 (fluticasone 500 microg plus salmeterol 50 microg/actuation), 1 inhalation b.i.d., in patients with severe asthma

Next Previous
Trial Profile

A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 microg plus formoterol 6 microg/actuation), 2 puffs b.i.d., versus beclomethasone diproprionate HFA (250 microg/actuation), 4 puffs b.i.d., versus Seretide 500/50 (fluticasone 500 microg plus salmeterol 50 microg/actuation), 1 inhalation b.i.d., in patients with severe asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Beclometasone; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Chiesi Farmaceutici

    • Most Recent Events

    • 03 Jul 2012 Additional trial location (Czech Republic) added as reported by European Clinical Trials Database record.
    • 03 Jul 2012 Actual end date (10 Sep 2009) added as reported by European Clinical Trials Database record.
    • 24 Aug 2011 Planned End Date changed to 14 Mar 2009.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top